Baxdrostat, a selective aldosterone synthase inhibitor, lowered BP and albuminuria in patients with uncontrolled hypertension ...

Study findings support intensive blood pressure control in patients with hypertension without chronic kidney disease at baseline.

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. You know, hypertension and chronic kidney ...

Study findings could have implications for implementing targeted evidence-based therapies to slow CKD progression. PHILADELPHIA—Undiagnosed early chronic kidney disease (CKD) is highly prevalent among ...

As the prevalence of both chronic kidney disease (CKD) and heart failure (HF) increases, therapies targeting shared pathways ...

The Phase 2 clinical trial, known as FigHTN, found that the new medication, baxdrostat, yielded a roughly 5% reduction in ...

Mortality from hypertensive kidney disease in the U.S. has grown by 48%, according to an abstract presented Sept. 5 at the American Heart Association’s 2025 Hypertension Scientific Sessions.

RADNOR, Pa., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...

The death rate from hypertensive kidney disease (high blood pressure-related kidney disease) increased by 48% in the U.S.

Childhood cancer survivors had an increased risk of chronic kidney disease and hypertension. Childhood cancer survivors had twofold and fourfold higher adjusted risks versus a hospitalized cohort and ...